Nature Reviews Drug Discovery contents November 2015 Volume 14 Number 11 pp 733-804

If you are unable to see the message below, click here to view.

Advertisement
Nature Medicine FOCUS ON INFLAMMATORY DISEASE  This series of Reviews highlights new data that point toward the influence of environmental factors and addresses recent advances in our knowledge of the cell types and signaling pathways involved in inflammatory disease onset and progression. Produced with support from Janssen Pharmaceutical Companies of Johnson & Johnson
TABLE OF CONTENTS
November 2015 Volume 14 Number 11
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity Natalie L. Trevaskis, Lisa M. Kaminskas & Christopher J. H. Porter
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Plants: Call for Papers Nature Plants launched in January and covers all aspects of plants be it their evolution, genetics, development or metabolism, their interactions with the environment, or their societal significance. The journal welcomes high quality submissions and encourages you and your colleagues to consider submitting your next research paper to the journal.  Submit your next research paper to the journal.
Comment: Tackling reproducibility in academic preclinical drug discovery Stephen V. Frye, Michelle R. Arkin, Cheryl H. Arrowsmith, P. Jeffrey Conn, Marcie A. Glicksman, Emily A. Hull-Ryde & Barbara S. Slusher p733 | doi:10.1038/nrd4737 The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Do you want chips with that? Asher Mullard p735 | doi:10.1038/nrd4769 Digital prescription pills, set to hit the market soon, offer the opportunity to address key drug adherence challenges in clinical practice and clinical trials. PDF
Antibacterial antibodies gain traction Chris Morrison p737 | doi:10.1038/nrd4770 First pivotal study win for Merck & Co.'s antibacterial antibody suggests that biologics could at last bring precision medicine to the anti-infective space. PDF
NEWS IN BRIEF FDA approves first immunotherapy combo Asher Mullard p739 | doi:10.1038/nrd4779 PDF
Roche hits multiple sclerosis landmarks Asher Mullard p739 | doi:10.1038/nrd4780 PDF
CETP set-back, again Asher Mullard p739 | doi:10.1038/nrd4781 PDF
BIOBUSINESS BRIEFS Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation Nicholas S. Downing, Harlan M. Krumholz, Joseph S. Ross & Nilay D. Shah p740 | doi:10.1038/nrd4734 PDF
BIOBUSINESS BRIEFS Trial watch: Telomerase inhibitor shows promise in myeloproliferative disorders Megan Cully p741 | doi:10.1038/nrd4762 PDF
AN AUDIENCE WITH Husseini Manji p742 | doi:10.1038/nrd4771 Husseini Manji, the Global Therapeutic Area Head of Neuroscience at Janssen, discusses the promise of NMDA receptor antagonists, anti-inflammatories and endocannabinoid modulators in psychiatry. PDF
FROM THE ANALYST'S COUCH The psoriasis drugs market Salman Rizvi, Kritika Chaudhari & Basharut A. Syed p745 | doi:10.1038/nrd4763 This analysis provides an overview of the current pipeline of drugs for psoriasis and an outlook for the psoriasis market, which is growing substantially. PDF
RESEARCH HIGHLIGHTS Top Cardiovascular disease: Patching up the heart p747 | doi:10.1038/nrd4764 PDF Muscle disorders: Combating cachexia in cancer p748 | doi:10.1038/nrd4765 PDF Neurodegenerative disease: Targeting tau acetylation attenuates neurodegeneration p748 | doi:10.1038/nrd4768 PDF Cancer: Antitumour responses with more BiTE p749 | doi:10.1038/nrd4767 PDF Drug delivery: Long live the peptides p750 | doi:10.1038/nrd4766 PDF IN BRIEF Inflammation: Siglec-targeting nanoparticle treats sepsis | Epigenetics: Targeting chromatin regulation in PDAC | Autoimmune disease: Novel peptide ameliorates CNS inflammation | Cancer: New RAF inhibitor with broad activity PDF Drug Discovery JOBS of the week Professor & Chair, Department of Physiology & Pharmacology Oregon Health and Science University (OHSU) Postdoctoral Scientist for Computational Genomics and Epigenomics Helmholtz Association Research Scientist (#79025) California Institute for Biomedical Research Postdoctoral Researcher -2321303 Eastern Virginia Medical School Postdoctoral Research Assistant (1 FTE) University of Dundee More Science jobs from Drug Discovery EVENT Liposomes in Drug and Vaccine Delivery 19.12.16 London, UK More science events from
Advertisement
Unmatched Fusion of LC-MS/MS Speed and Sensitivity Shimadzu's LCMS-8060 features a polarity switching time of 5 msec, a data acquisition scan speed of 30,000 u/sec, and ultra-fast MRM measurements, while its redesigned ion guide and robust design ensure the utmost in quantitative detection, making it ideal for a wide array of applications. Learn more.
PERSPECTIVES		Top
OPINION Hit and lead criteria in drug discovery for infectious diseases of the developing world Kei Katsuno, Jeremy N. Burrows, Ken Duncan, Rob Hooft van Huijsduijnen, Takushi Kaneko, Kiyoshi Kita, Charles E. Mowbray, Dennis Schmatz, Peter Warner & B. T. Slingsby p751 | doi:10.1038/nrd4683 The quality of the chemical starting points for small-molecule drug discovery is a key factor in improving the likelihood of clinical success. In this article, experts from several organizations involved in drug discovery for malaria, tuberculosis and neglected tropical diseases present disease-specific criteria for hits and leads, and discuss the underlying rationale. Abstract | Full Text | PDF
Advertisement
Nature Reviews Drug Discovery Special on targeting the IL-17 pathway in inflammatory disease  POSTER - Targeting the IL-17 pathway in inflammatory disease ANIMATION - Tumour immunology and immunotherapy  Animation and Poster produced with support from  Eli Lilly and Company
REVIEWS		Top
Targeting protein aggregation for the treatment of degenerative diseases Yvonne S. Eisele, Cecilia Monteiro, Colleen Fearns, Sandra E. Encalada, R. Luke Wiseman, Evan T. Powers & Jeffery W. Kelly p759 | doi:10.1038/nrd4593 The misfolding and aggregation of specific proteins — a process known as amyloidogenesis — seem to underlie a range of degenerative disorders. Here, Kelly and colleagues discuss the current understanding of the process and pathological role of protein aggregation, focusing on emerging disease-modifying strategies to ameliorate aggregation-associated degenerative disorders. Abstract | Full Text | PDF
From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity Natalie L. Trevaskis, Lisa M. Kaminskas & Christopher J. H. Porter p781 | doi:10.1038/nrd4608 Targeted delivery to the lymphatic system has the potential to improve bioavailability, enhance prophylactic and therapeutic vaccination or tolerance induction, and target drug delivery to lymph-resident infection or metastasis. In this Review, Trevaskis, Kaminskas and Porter provide an overview of lymphatic targeting and delivery strategies in drug development, and discuss the clinical applications of these approaches. Abstract | Full Text | PDF
Corrigendum: Alzheimer antibody drugs show questionable potential Sara Reardon p804 | doi:10.1038/nrd4772 Full Text | PDF
Advertisement
Primers in your inbox Nature Reviews Disease Primers launched in April 2015 and publishes Primers — introductory review articles that provide overviews of diseases and disorders. Primer articles describe all aspects of a condition: epidemiology; disease mechanisms; diagnosis, screening and prevention; management; and quality of life.  Stay updated on the latest Primers published.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.